Kwality Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Kwality Pharmaceuticals is strategically transitioning towards high-margin therapeutic segments, particularly oncology and biologics, which is expected to drive revenue growth and margin expansion. Management's focus on an asset-light out-licensing model and aggressive regulatory filings supports this shift, with the successful commercialization of its EPO biosimilar anticipated in H1 FY27. Despite recent gross margin pressures from raw material costs, the company's strong balance sheet and operational improvements position it well for future growth. Vista's financial outlook reflects a moderate revenue growth trajectory, with improving margins expected as the company capitalizes on its specialized manufacturing capabilities. The favorable macro environment in India, characterized by stable inflation and strong manufacturing activity, further supports Kwality's growth potential. Over the next 12-24 months, key opportunities include the successful launch of new products and expansion into regulated markets, while watchpoints include the execution of clinical trials and geopolitical risks affecting cash flows
Why We Like This Stock
- Strategic pivot towards high-margin oncology and biologics segments enhances revenue potential
- Strong balance sheet supports capex for facility upgrades and clinical trials
- Favorable macroeconomic conditions in India bolster growth prospects
Things To Watch Out For
- Execution risks associated with clinical trials and regulatory approvals
- Geopolitical tensions may impact cash conversion cycles
- Recent gross margin pressures due to rising raw material costs
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 307 | 370 | 503 | 593 | 715 |
| Profit Before Tax (Cr.) | 38 | 54 | 90 | 128 | 147 |
| PBT Margin | 12.4% | 14.6% | 1785.9% | 21.5% | 20.6% |
| Net Profit (Cr.) | 29 | 40 | 67 | 95 | 109 |
| Earnings Per Share | 27.6 | 38.2 | 64.8 | 91.2 | 105.4 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, and various other categories such as general, beta-lactam, cephalosporins, cytotoxic (oncology), and biological. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.